<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">NIEDER, CARSTEN</style></author><author><style face="normal" font="default" size="100%">YOBUTA, ROSALBA</style></author><author><style face="normal" font="default" size="100%">MANNSÅKER, BÅRD</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">173-176</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.11455</style></doi><volume><style face="normal" font="default" size="100%">33</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The aim of this study was to analyze the patterns of treatment and outcomes in patients with a large number of brain metastases, arbitrarily defined as 20 or more lesions. These patients are typically excluded from studies of focal brain treatment, e.g., surgery or radiosurgery, and might have a limited prognosis. Patients and Methods: This was a retrospective single-institution analysis. Overall, 11 patients were identified from a prospectively maintained database. Results: Ten patients had received active treatment (9 whole-brain radiotherapy, 7 systemic therapy). Median survival was 5.0 months without long-term survival beyond 13 months. Patients with better performance status had numerically longer survival, however we did not identify baseline parameters with a significant impact on survival. Conclusion: While long-term survival was not observed in this small study, most patients survived long enough to experience symptomatic improvement from whole-brain radiotherapy. Therefore, we recommend multidisciplinary assessment of the patients' prognosis and systemic treatment options, and initiation of whole-brain radiotherapy if survival is not limited to 1-2 months.</style></abstract></record></records></xml>